利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.024 秒)

    Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
    1.
    发明授权
    Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women 有权
    性固醇前体单独或与选择性雌激素受体调节剂和/或与雌激素和/或5型cGMP磷酸二酯酶抑制剂组合用于预防和治疗绝经后妇女的阴道干燥和性功能障碍

    公开(公告)号：US08835413B2

    公开(公告)日：2014-09-16

    申请号：US11255617

    申请日：2005-10-20

    申请人： Mohamed El-Alfy ,  Fernand Labrie ,  Louise Berger

    发明人： Mohamed El-Alfy ,  Fernand Labrie ,  Louise Berger

    IPC分类号： A61K31/56 ,  A61K31/445 ,  A61K31/35 ,  A61K31/566 ,  A61K31/453 ,  A61K31/519 ,  A61K31/5685

    CPC分类号： A61K31/5685 ,  A61K31/453 ,  A61K31/519 ,  A61K31/566

    摘要： Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance , in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

    摘要翻译： 在涉及施用性类固醇前体的易感染的温血动物（包括人）中治疗或减少获得阴道功能障碍的可能性的更多方法，特别是阴道干燥和性交痛，导致性功能障碍和性欲降低和表现。 进一步施用雌激素或选择性雌激素受体调节剂，特别是选自雷洛昔芬，阿唑西芬，他莫昔芬，德洛昔芬，托瑞昔芬，碘多昔芬，GW 5638，TSE-424，ERA-923和拉索昔芬的那些，更具体地， 一般结构：具体公开用于治疗和/或抑制某些上述疾病的发展。 还公开了用于递送本发明有用的活性成分和试剂盒的药物组合物。

    Sex steroid precursor alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
    2.
    发明申请
    Sex steroid precursor alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women 有权
    性类固醇前体单独或与选择性雌激素受体调节剂和/或与雌激素和/或5型cGMP磷酸二酯酶抑制剂组合用于预防和治疗绝经后妇女的阴道干燥和性功能障碍

    公开(公告)号：US20070270394A1

    公开(公告)日：2007-11-22

    申请号：US11255617

    申请日：2005-10-20

    申请人： Mohamed El-Alfy ,  Fernand Labrie ,  Louise Berger

    发明人： Mohamed El-Alfy ,  Fernand Labrie ,  Louise Berger

    IPC分类号： A61K31/56 ,  A61K31/352 ,  A61K31/5025 ,  A61P15/02 ,  A61K31/519

    CPC分类号： A61K31/5685 ,  A61K31/453 ,  A61K31/519 ,  A61K31/566

    摘要： Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance , in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

    摘要翻译： 在涉及施用性类固醇前体的易感染的温血动物（包括人）中治疗或减少获得阴道功能障碍的可能性的更多方法，特别是阴道干燥和性交痛，导致性功能障碍和性欲降低和表现。 进一步施用雌激素或选择性雌激素受体调节剂，特别是选自雷洛昔芬，阿唑西芬，他莫昔芬，德洛昔芬，托瑞昔芬，碘多昔芬，GW 5638，TSE-424，ERA-923和拉索昔芬的那些，更具体地， 一般结构：具体公开用于治疗和/或抑制某些上述疾病的发展。 还公开了用于递送本发明有用的活性成分和试剂盒的药物组合物。

    Use of androgens to reduce the likelihood of acquiring or to treat skin aging
    7.
    发明申请
    Use of androgens to reduce the likelihood of acquiring or to treat skin aging 审中-公开
    使用雄激素以减少获得或治疗皮肤老化的可能性

    公开(公告)号：US20060178352A1

    公开(公告)日：2006-08-10

    申请号：US11264704

    申请日：2005-11-01

    申请人： Mohamed El-Alfy ,  Fernand Labrie ,  Lamia Azzi

    发明人： Mohamed El-Alfy ,  Fernand Labrie ,  Lamia Azzi

    IPC分类号： A61K31/57

    CPC分类号： A61K31/57 ,  A61K8/63 ,  A61K31/568 ,  A61Q19/08

    摘要： Novel methods of treating or reducing the likelihood of acquiring skin diseases due to age-related androgen deficiency, particularly skin atrophy, loss of collagen, loss of elastic fibers, loss of connective tissue, cellulite, and formation of wrinkles, in susceptible warm-blooded animals including humans involving administration of an androgen or/and a sex steroid precursor. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

    摘要翻译： 治疗或减少由于年龄相关的雄激素缺乏，特别是皮肤萎缩，胶原损失，弹性纤维丧失，结缔组织丢失，脂肪团和皱纹形成的易感性温血的可能性的新方法 包括涉及雄激素或/和性类固醇前体的施用的动物。 还公开了用于递送本发明有用的活性成分的药物组合物。